Northwell Opens $1.5M Multidisciplinary Practice in Smithtown, New York

Northwell Health today announced the opening of a $1.5 million, 4,000-square-foot multidisciplinary practice at 222 Middle Country Road in Smithtown. The Northwell Health Physician Partners office, part of an existing office building, will provide both primary care services as well as several other specialties.

The third-floor office will house three internal medicine physicians, rheumatology, gastroenterology, cardiology, surgical oncology and dermatology. The space will include 10 exam rooms. The three internal medicine physicians are Claude Bridges, MD, Berta Kadosh, DO and Deborah Weiss, MD.

“With this opening Northwell continues our ongoing expansion of delivering high-quality medical care in Suffolk County,” said Mark Talamini, MD, MBA, FACS, senior vice president and executive director of Northwell Health Physician Partners. “It also reaffirms our commitment to providing easy access to a range of different services, more quickly in the neighborhoods in which our patients live and work.”

The specialists complement an existing Physician Partners practice already in the building catering to urology, colon and rectal surgery, obstetrics and gynecology, pediatrics, labs and orthopedics.

“Northwell is extremely excited to open this beautiful destination practice,” said Joseph Baglio, senior vice president of Eastern Region Ambulatory Services at Northwell Health. “This location is another demonstration of Northwell’s commitment to integrated, multidisciplinary, care within the communities we serve.”

Located on Middle Country Road near Route 111, this modern practice is easily accessible and within proximity to Huntington Hospital. The new facility provides much needed access to primary care to everyone in the surrounding community.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version